Why the study?
Does a 21-day inpatient cardiac rehabilitation program combined with pharmacological therapy optimization improve functional capacity and reduce NT-proBNP levels in a patient with severe HFrEF following complex PCI for NSTEMI?
Case Report (n=1)
No
Does a 21-day inpatient cardiac rehabilitation program combined with pharmacological therapy optimization improve functional capacity and reduce NT-proBNP levels in a patient with severe HFrEF following complex PCI for NSTEMI?
In a patient with severe ischemic HFrEF (LVEF <25%) following Impella-assisted complex PCI for NSTEMI, a 21-day inpatient cardiac rehabilitation program paired with transition to sacubitril/valsartan resulted in a 57.5% reduction in NT-proBNP and restoration of independent ambulation.
Answers are grounded in this paper and cite their sources.
Single-case data on combined inpatient rehabilitation and sacubitril/valsartan; leaves open confirmation of benefit in severe HFrEF.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pracaić et al. (2026) conducted a case report in Ischemic cardiomyopathy with heart failure with reduced ejection fraction (HFrEF) following NSTEMI and complex PCI (n=1). Inpatient cardiac rehabilitation and guideline-directed medical therapy optimization (sacubitril/valsartan and ezetimibe/atorvastatin) was evaluated on NT-proBNP levels and functional capacity (six-minute walk test).
Synapse has enriched 10 related papers. Consider them for comparative context: